Stuart Nelson

Stuart Nelson is a professional in gene therapy with extensive experience in analytical development and biotechnology. They worked as a Research Associate II and I at MassBiologics from 2014 to 2016, and held various roles at Prevail Therapeutics from 2019 to 2021, including Senior Scientist in Analytical Development. Currently, Stuart serves as a Scientific Advisory Board Member at QIAGEN, a CMC Committee Member for the American Society of Gene & Cell Therapy, and as a Senior Advisor at Eli Lilly and Company. They are pursuing an M.S. in Biotechnology and Biomedical Science at UMass Boston and have a B.S. in Molecular Biology from Keene State College.